Drug intelligence / Profile preview

RHA 3

Development stage
Unknown
Lead developer
Teoxane
Modality
Recombinant Proteins and Enzymes, Small Molecules
Administration
Subcutaneous, Intradermal
01

Overview

RHA 3 is a **gel implant (dermal filler)** consisting of cross-linked **hyaluronic acid**, stabilized with 1,4-butanediol diglycidyl ether and containing 0.3% lidocaine to minimize injection pain. It is injected into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds, and is also indicated for lip augmentation and enhancing lip fullness in adults. The hyaluronic acid is designed to be resilient and adapt to dynamic facial movements, providing natural-looking and long-lasting results, typically lasting up to 12–15 months. The filler is manufactured using technology that preserves the natural properties of hyaluronic acid, allowing for flexibility and strength in areas of frequent movement.

Brand names
RHA 3RHA3RHA-3
Other names
Resilient Hyaluronic Acid 3
02

Targets

SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)

Beyond the preview

Go deeper on RHA 3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RHA 3.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call